A quantitative autoradiographic method for the determination of local rates of protein synthesis in brain in vivo is being developed. The method employs L-[1-'4C]leucine as the radiolabeled tracer. A comprehensive model has been designed that takes into account intracellular and extracellular spaces, intracellular compartmentation of leucine, and the possibility of recycling of unlabeled leucine derived from steadystate degradation of protein into the precursor pool for protein synthesis. We have evaluated the degree of recycling by measuring the ratio of the steady-state precursor pool distribution space for labeled leucine to that of unlabeled leucine. The values obtained were 0.58 in whole brain and 0.47 in liver. These results indicate that there is significant recycling of unlabeled amino acids derived from steady-state protein degradation in both tissues. Any method for the determination of rates of cerebral protein synthesis in vivo with labeled tracers that depends on estimation of precursor pool specific activity in tissue from measurements in plasma must take this recycling into account.
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The autoradiographic deoxyglucose method (1) for measurement of local cerebral glucose utilization provides a useful model for the design of methods to determine local rates of biochemical processes within tissues in vivo. We have used the same general approach to develop a method for the quantitative determination of local rates of protein synthesis, or, more precisely, amino acid incorporation into protein, in the nervous system (2, 3) . The method is an application of the basic principles for the assay of rates of chemical reactions with isotopes adapted for the special conditions encountered in vivo (4) . Briefly, the total amount of labeled product specific to the reaction of interest (in this case labeled protein) formed in the selected tissue over an interval of time is divided by the integrated specific activity (SA) of the precursor pool over the same interval and corrected for any isotope effect (4) . This relationship can be expressed as follows:
where Ri equals rate of the overall reaction in tissue i, P*' is amount of labeled product formed in tissue i between zero time and time T, (Cpp/Cpp)(t) is the ratio of the concentration of labeled tracer to that of the endogenous unlabeled substrate (i.e., SA) in the precursor pool at any time t, and 4 is a correction for any isotope effect. If there is no isotope effect, 'I = 1.
The application of these principles to in vivo conditions is complicated, however, because the necessary variables readily measured directly in vitro must be determined indirectly in vivo. Quantitative autoradiography, for example, is used to achieve spatial localization of the label in the tissues, but it cannot distinguish between radiochemical species. It measures only total concentration of isotope and not the concentrations of the specific products of the reaction of interest. Unreacted labeled precursor molecules and labeled products of other biochemical reactions may also be present. In addition, some of the labeled products of the specific reaction under study may be removed from the tissue by the blood flow during the experimental period. Procedures must, therefore, be designed to avoid or correct for loss of specific product and presence of other labeled compounds. Another problem is the determination of the integrated SA of the precursor pool. Its direct determination would require measurement of the complete time courses of the concentrations oftracer and endogenous precursor compounds in each tissue of interest. This is obviously impossible in a conscious behaving animal. Instead, the time course of the SA in blood or plasma is measured, and correction is made for the effects of the lag of the tissue behind the blood or plasma and possible differences in the distribution spaces for the labeled and unlabeled precursors.
In our initial approach we attempted to deal with these problems in the design of the kinetic model and the experimental procedures (2, 3) . Radioactive products of extraneous biochemical reactions were avoided by selection of L-[1-'4C]leucine as the labeled precursor. Carboxyl-labeled leucine, like other aliphatic, branched-chain amino acids, is either incorporated into protein or metabolized by only one pathway beginning with transamination rapidly followed by decarboxylation (5) . Metabolized [1-'4C] leucine loses its label to 14CO2, which is rapidly removed from brain by the circulation. Reincorporation of label from 14CO2 is negligible because of its dilution with the CO2 produced by glucose metabolism in brain. Therefore, 14C remaining in the tissue exists only in labeled protein or free leucine. The administration of [1-14C] [2] and the operational equation reduces to C* (T)
The only variable in Eq. 3 not measured directly in each experiment is A, which must be evaluated separately. The values of the rate constants of which A is composed (Fig. 1B) need not be individually determined to evaluate A. A can be determined experimentally on the basis of its functional definition as the ratio of the steady-state distribution ratios of labeled and unlabeled leucine between the precursor pool in the tissue and the arterial plasma (i.e., the ratio of the precursor pool distribution space for labeled leucine to that of unlabeled leucine). Therefore, (C~/Co) A=(CP*P/C*) [4] By algebraic rearrangement A equals the ratio of the SAs of leucine in the precursor pool and plasma. Thus, (C* /CPP) A = (C /C) [5] Eq. 5 provides the theoretical basis for the experimental evaluation of A. The immediate amino acid precursors for protein synthesis are tRNA-bound and can be isolated from other amino acid pools. To determine A, a constant SA of leucine in arterial plasma is maintained until the brain reaches a steady state. The steady-state SAs of leucine in plasma and in brain aminoacyl-tRNA are then measured, and A is calculated by Eq. 5. Experimental Procedure to Determine A. Infusion schedules designed to achieve and maintain constant arterial plasma concentrations of labeled leucine for at least 60 min were determined by the method of Patlak and Pettigrew (13) . A tracer dose of [3H]leucine (7-10 mCi) was infused by way of the venous catheter according to the schedule by means of a computer-driven infusion pump. [3H]Leucine was used to determine A because higher SAs were needed to measure the very small amounts of tRNA-bound leucine in brain. The infusions were continued for =30 min (three rats) or -60 min (three rats). Timed arterial blood samples were drawn every 5 min during the infusion and centrifuged immediately to separate the plasma, which was deproteinized in 5% (wt/vol) trichloroacetic acid and stored at -20'C until assayed for leucine and [3H]leucine concentrations. At the end of the infusion rats were decapitated, and brains and livers were quickly removed and chilled to 0C in ice-cold 0.25 M sucrose.
MATERIALS AND METHODS
Extraction and Purification of Aminoacyl-tRNA. Brain and liver from each animal were homogenized separately in 5 ml of 0.25 M sucrose (00C) per g containing 10 mM vanadyl ribonucleoside complex to inhibit ribonuclease and 6 mg of uncharged tRNA added as a carrier. The homogenates were centrifuged at 100,000 x g for 1 hr. The pellets, which contained most of the RNA with high molecular weights, were discarded. The cytosolic protein and RNA were precipitated in 5% (wt/vol) trichloroacetic acid and removed by centrifugation (12,000 x g, 20 min). The supernatant solutions were stored at -70°C until assayed for [3H]leucine SA. The precipitates containing the aminoacyl-tRNA were washed three times each in 3% (wt/vol) and 0.06% (wt/vol) HC104 to remove any remaining free amino acids, suspended in 0.3 M NaOAc (pH 5), and extracted with an equal volume of fresh water-saturated phenol containing 0.1% (wt/vol) 8-hydroxyquinoline as an antioxidant. The aqueous phase containing the aminoacyl-tRNA was separated, and residual phenol was removed by five extractions with diethylether. The aminoacyl-tRNA was precipitated overnight at -20°C following addition of 2.5 volumes of ethanol containing 0.12 M KOAc. The RNA precipitate was recovered by centrifugation at 0°C; washed three times in a 1:2.5 (vol/vol) mixture of 0.3 M NaOAc, pH 5/0.12 M KOAc in ethanol; dissolved in 0.3 ml of 50 mM Na2CO3 (pH 10); and incubated at 37°C for 90 min to deacylate aminoacyl-tRNA. Deacylated tRNA was precipitated overnight at -20°C by addition of 2.5 volumes of ethanol and removed by centrifugation (12,000 X g, 20 min). The supernatant solutions, which contained the previously tRNA-bound amino acids, were dried in a stream of N2 and stored at -20°C until analyzed further.
Assay of SA of [3H]Leucine by Derivatization with [14C]-
Dns-Cl. Amino acids in deproteinized plasma and acidsoluble fractions of cytosol from brain and liver were further purified by Dowex 50-H+ column (2 x 0.5 cm) chromatography. The effluents from the columns were discarded, and the amino acids were eluted with 25-30% (wt/vol) NH40H. The eluates were evaporated to dryness and redissolved in 50 mM Na2CO3 (pH 10). The fractions containing the amino acids recovered from the deacylation of the tRNA extracted stopped by addition of 2 pl of 88% (wt/vol) formic acid and 20 nmol of unlabeled Dns-leucine as carrier. Dns-leucine was purified from the reaction mixtures by the following procedure. The reaction mixtures were loaded onto Sep-Paks (Waters Associates). Dns-OH was first selectively eluted with 0.1% (wt/vol) acetic acid in 25% (vol/vol) methanol, and then the dansylated amino acids were eluted with 0.1% acetic acid in 100% methanol. The eluates were dried in a stream of N2, dissolved in acetone, and subjected to two-dimensional TLC on polyamide plates (15 x 15 cm) . The solvent systems were 1.8% (wt/vol) formic acid for the first dimension and benzene/acetic acid, 9:1 (vol/vol), for the second (14) . The Dns-leucine spot was identified by UV fluorescence and cut out, and the Dns-leucine was eluted with acetone. The eluates were dried in a stream of N2 and dissolved in 25 Al of 0.2 mM unlabeled carrier Dns-leucine in methanol. The Dns-leucine was isolated by reverse-phase HPLC on a 5-gm C18 column (150 x 4.6 mm). Samples were eluted at 1.2 ml/min over 30 min at room temperature with a linear gradient of 25-40% (vol/vol) acetonitrile in 15 mM orthophosphoric acid/8.6 mM triethylamine. Fractions were collected every 0.2 min, and those within the Dns-leucine peak, identified by fluorescence, were pooled, dried, dissolved in acetonitrile, and assayed for 3H and 14C by liquid scintillation spectroscopy (model LS 5801, Beckman). Counting efficiencies for 3H and 14C were 26% and 60%, respectively; spillover of 14C into the 3H channel was 6%. From Fig. 2 ) SA of [3H]leucine was determined by liquid scintillation spectroscopy and assay of leucine by direct amino acid analysis. The samples were prepared as described above to the point of dansylation, then dried in a stream of N2, dissolved in 0.5 ml of water, filtered through a 0.45-,m filter (Millipore), dried again, and redissolved in 100-200 ,l of 0.2 M sodium citrate (pH 2.2). Amino acids in these samples were analyzed by post-column derivatization with o-phthalaldehyde and fluorimetric assay in a Beckman model 7300 amino acid analyzer. This system could measure 25-50 pmol of leucine (the range in the experimental samples) with a 3% error. Fractions, after passage through the detector, were collected every 0.25 min and assayed for 3H by liquid scintillation spectroscopy. SA was calculated from total 3H in all fractions in the leucine peak and the total leucine content was measured.
RESULTS
In six experiments the SA of [3H]leucine in arterial plasma was maintained relatively constant long enough (30-60 min) for the leucine pools in brain and liver to reach steady states with respect to plasma. In all experiments the SAs of the tRNA-bound leucine in brain and liver were below those of the arterial plasma (Table 1 ; Fig. 2 ). According to Eq. 5, the steady-state distribution spaces of the labeled leucine in the precursor pools for protein synthesis averaged 58% (A = 0.58) and 47% (A = 0.47) of the equivalent distribution spaces for the unlabeled leucine in brain and liver, respectively. The values in brain at 30 and 60 min were not significantly different, indicating that a steady state had indeed been achieved. Amounts of tRNA-bound [3H]leucine and unlabeled leucine recovered from brain were small-i.e., 500-1500 dpm and 17-57 pmol, respectively. In all experiments except E (Table 1 ; Fig. 2E ), the SA of [3H]leucine was determined by the double-label [14Cldansylation procedure; in experiment E, leucine was assayed by amino acid analysis with o-phthalaldehyde derivatization. The results were sim- ilar with both analytical techniques. The ratio of the distribution spaces for labeled and unlabeled leucine in the total acid-soluble pool of brain was 0.59, essentially the same as that for tRNA-bound leucine (Table 1) .
DISCUSSION
The results of these studies show that in brain and liver of normal, conscious, adult rats there is significant recycling of leucine derived from protein degradation into the total acid-soluble amino acid pool and the precursor pool for protein synthesis. These findings confirm previous results in rat liver (15, 16) , which showed that about 50% of the free amino acid pool is derived from protein catabolism. Our results also indicate that the degree of recycling is comparable in brain. Brain and liver appear then to be different from heart (17) , where tRNA-bound labeled leucine has been reported to reach complete isotopic equilibrium with plasma leucine. Our results in brain do not agree with a recent preliminary report (18) The four-compartment model in Fig. 1A takes into account all possible routes by which recycling of leucine might occur. Although A (Fig. 1B) is expressed in terms of the rate constants that characterize these routes, in the present studies the values for A were determined experimentally on the basis of a direct, operational definition (Eq. 5) and are valid regardless of the relationships among the tissue compartments. The value in brain, however, applies only to the brain as a whole in normal, awake rats. Its variation in brain regions and its stability in different biological states are unknown. We must now attempt to determine A locally in different brain regions. A regional method would also facilitate examination of its stability in different experimental states. With a regional method for determining A it would become possible to distinguish between changes in rates of protein synthesis and rates of protein degradation. Dunlop et al. (19) have proposed "flooding" the amino acid pools with massive loading doses of radioactive valine to dilute the effects of recycling of unlabeled valine. Examination of the effects of "flooding" doses of leucine on A is necessary to determine whether they raise its value toward unity. 
